Paraic Kenny, PhD, Gundersen Medical Foundation, La Crosse, WI, comments on the anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate (ADC) targeting cell surface cleaved amphiregulin in breast cancer. Amphiregulin is a key proliferative effector of estrogen receptor signaling in breast cancer and other malignancies. A residual transmembrane stalk, that is the byproduct of amphiregulin cleavage, is the target of GMF-1A3, and the ADC was shown to be cytotoxic and induce rapid regression of breast tumor xenografts in mice. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
